ASCO/EHA/ICML 2021 – Roger Owen
Roger Owen summarizes the status of emerging therapeutic agents for the treatment of patients with Waldenström’s macroglobulinemia, highlights those that appear most promising, even after failing BTK inhibitors, talks about how to guide treatment decisions, the influence of the mutation profile and expectations of BTK inhibitors in patients with relapsed and refractory marginal zone lymphoma.
Here is the full ASCO/EHA/ICML 2021 report.
More posts
Zanubrutinib in relapsed/refractory marginal zone lymphoma: MAGNOLIA
Zanubrutinib in relapsed/refractory marginal zone lymphoma: MAGNOLIA B-cell rec
Mantle cell lymphoma: improving outcomes in difficult-to-treat patient populations
Mantle cell lymphoma: improving outcomes in difficult-to-treat patient populations
Extending anti-PD-1–based options in the setting of Hodgkin lymphoma
Extending anti-PD-1–based options in the setting of Hodgkin lymphoma Patients w
Successful inhibition of PI3K, BTK, BCL2 and other targets in various B-cell malignancies
Successful inhibition of PI3K, BTK, BCL2 and other targets in various B-cell malign
Waldenström’s macroglobulinemia: outcome optimization via combinations
Waldenström’s macroglobulinemia: outcome optimization via combinations Final an
CLL/SLL: current perspectives across a range of potent agents
CLL/SLL: current perspectives across a range of potent agents ALPINE: zanubruti
